Indicators of carbohydrate metabolism in a patient with dyslipidemia and impaired fasting glycemia receiving pitavastatin: a case report
https://doi.org/10.15829/1728-8800-2022-3496
Abstract
Statins have diabetogenic properties. Pitavastatin is currently considered the only drug in this group that combines high lipid-correcting activity with the absence of a negative effect on carbohydrate metabolism. The article presents a case of correction of carbohydrate metabolism indicators against the background of pitavastatin therapy in a patient with dyslipidemia and impaired fasting glycemia. The optimal algorithms for the examination and treatment of such patients are discussed on the example of this patient.
About the Authors
A. A. Nekrasov
Volga Research Medical University; City Clinical Hospital № 5
Russian Federation
Russian Federation
Nizhny Novgorod
E. S. Timoshchenko
City Clinical Hospital № 5
Russian Federation
Russian Federation
Nizhny Novgorod
D. V. Cherneva
City Clinical Hospital № 5
Russian Federation
Russian Federation
Nizhny Novgorod
I. N. Volovatova
Volga Research Medical University
Russian Federation
Russian Federation
Nizhny Novgorod
T. A. Nekrasova
Volga Research Medical University
Russian Federation
Russian Federation
Nizhny Novgorod
References
1. Verbovoy AF, Verbovaya NI, Dolgikh YuA. Obesity is the basis of metabolic syndrome. Obesity and metabolism. 2021;18(2):142-9. (In Russ.) doi:10.14341/omet12707.
2. German CA, Baum SJ, Ferdinand KC, et al. Defining preventive cardiology: A clinical practice statement from the American Society for Preventive Cardiology. Am J Prev Cardiol. 2022;12:100432. doi:10.1016/j.ajpc.2022.100432.
3. Alferova VI, Mustafina SV. The prevalence of obesity in the adult population of the Russian Federation (literature review). Obesity and metabolism. 2022;19(1):96-105. (In Russ.) doi:10.14341/omet12809.
4. Badin YuV, Fomin IV, Belenkov YuN, et al. EPOCHA-AH 1998-2017. Dynamics of prevalence, awareness of arterial hypertension, treatment coverage, and effective control of blood pressure in the European part of the Russian Federation. Kardiologiia. 2019;59(1S):34-42. (In Russ.) doi:10.18087/cardio.2445.
5. Drapkina OM, Kontsevaya AV, Kalinina AM, et al. 2022 Prevention of chronic non-communicable diseases in the Russian Federation. National guidelines. Cardiovascular Therapy and Prevention. 2022;21(4):3235. (In Russ.) doi:10.15829/17288800-2022-3235.
6. Shestakova MV, Vikulova OK, Zheleznyakova AV, et al. Diabetes epidemiology in Russia: what has changed over the decade? Therapeutic Archive. 2019;91(10):4-13. (In Russ.) doi:10.26442/00403660.2019.10.000364.
7. Seo WW, Seo SI, Kim Y, et al. Impact of pitavastatin on new-onset diabetes mellitus compared to atorvastatin and rosuvastatin: a distributed network analysis of 10 real-world databases. Cardiovasc Diabetol. 2022;21(1):82. doi:10.1186/s12933-022-01524-6.
8. Sadeq A, Elnour AA, Farah HF, et al. A systematic review of randomized clinical trials on the efficacy and safety of pitavastatin. Curr Rev Clin Exp Pharmacol. 2022. doi:10.2174/2772432817666220531115314.
9. Trias F, Pintó X, Corbella E, et al. Differences in the diabetogenic effect of statins in patients with prediabetes. The PRELIPID study. Med Clin (Barc). 2022;158(11):531-9. doi:10.1016/j.medcli.2021.06.018.
10. Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305(24):2556-64. doi:10.1001/jama.2011.860.
11. Alagona PJr. Pitavastatin: evidence for its place in treatment of hypercholesterolemia. Core Evid. 2010;5:91-105. doi:10.2147/CE.S8008.
12. Yokote K, Shimano H, Urashima M, et al. Efficacy and safety of pitavastatin in Japanese patients with hypercholesterolemia: LIVES study and subanalysis. Expert Rev Cardiovasc Ther. 2011;9(5):555-62. doi:10.1586/erc.11.47.
13. Yoon D, Sheen SS, Lee S, et al. Statins and risk for new-onset diabetes mellitus. A real-world cohort study using a clinical research database. Medicine. 2016;95(46):e5429. doi:10.1097/MD.0000000000005429.
14. Na E, Cho S, Kim DJ, et al. Time-varying and dose-dependent effect of long-term statin use on risk of type 2 diabetes: a retrospective cohort study. Cardiovasc Diabetol. 2020;19(1):111. doi:10.1186/s12933-020-01037-0.
15. Yamazaki T, Kishimoto J, Ito C, et al. Japan Prevention Trial of Diabetes by Pitavastatin in Patients with Impaired Glucose Tolerance (the J-PREDICT study): rationale, study design, and clinical characteristics of 1269 patients. Diabetol Int. 2011;2:13440. doi:10.1007/s13340-011-0032-0.
16. Zhao W, Zhao SP. Different effects of statins on induction of diabetes mellitus: an experimental study. Drug Des Devel Ther. 2015;9:6211-23. doi:10.2147/DDDT.S87979.
17. Chrusciel P, Sahebkar A, Rembek-Wieliczko M, et al. Impact of statin therapy on plasma adiponectin concentrations: a systematic review and meta-analysis of 43 randomized controlled trial arms. Atherosclerosis. 2016;253:194-208. doi:10.1016/j.atherosclerosis.2016.07.897.
18. Tanyanskiy DA, Denisenko AD. The influence of adiponectin on carbohydrates, lipids, and lipoproteins metabolism: analysis of signaling mechanisms. Obesity and metabolism. 2021;18(2):103-11. (In Russ.) doi:10.14341/omet12754.
19. Sedykh DYu, Khryachkova ON, Kashtalap VV, et al. Treatment of comorbid patients with dyslipidemia in real clinical practice: the possibilities of pitavastatin. RMJ. Medical review. 2021;5(4):218-24. (In Russ.) doi:10.32364/2587-6821-2021-5-4-218-224.
20. Ezhov MV, Sergienko IV, Alekseeva IA. Pitavastatin (Livazo) in the treatment of dyslipidemia in routine clinical practice in Russia. Russian programme "LEADER". Atherosclerosis and dyslipidemia. 2020;3(40):5-14. (In Russ.) doi:10.34687/2219-8202.JAD.2020.03.0001.
21. Ridker PM, Danielson E, Fonseca FAH, et al., for the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-207. doi:10.1056/NEJMoa0807646.
22. Algorithms of specialized medical care for patients with diabetes mellitus. Edited by I. I. Dedov, M. V. Shestakova, A. Yu. Mayorova. — 10th edition (updated). Diabetes mellitus. 2021;24(S1):1-148. (In Russ.) doi:10.14341/DM12802.
Supplementary files
Review
For citations:
Nekrasov A.A., Timoshchenko E.S., Cherneva D.V., Volovatova I.N., Nekrasova T.A. Indicators of carbohydrate metabolism in a patient with dyslipidemia and impaired fasting glycemia receiving pitavastatin: a case report. Cardiovascular Therapy and Prevention. 2022;21(12):3496. (In Russ.) https://doi.org/10.15829/1728-8800-2022-3496
Views:
1171
Email this article 
